PharmaLectures.com

Courses › Pharma industry foundations › Who sets the price of a pill: pricing and reimbursement in Europe's big markets

Who sets the price of a pill: pricing and reimbursement in Europe's big markets

Your team files European price dossiers that answer the payer before the payer asks.

Market access in pharma is the work of getting a medicine priced and reimbursed so patients can actually receive it once it has a marketing authorisation. In Europe each country decides on its own. Germany runs an early benefit assessment under its AMNOG law, France rates added benefit through the HAS before a price is negotiated, England relies on NICE technology appraisals, and Italy and Spain negotiate through national price committees. Since January 2025 the EU HTA Regulation adds joint clinical assessments for some new medicines. With this course, your market access team sees how a price is set in each big market.

  • 10 audio modulesthree lengths each
  • 1 h 40 min to 8 h 20 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • BD, finance, managementwho it is written for

Why market access pharma training matters

Your German dossier reaches the Federal Joint Committee, which finds no added benefit because the comparator was wrong. Launches elsewhere in Europe wait while the team rebuilds the evidence. The revenue plan finance showed the board is out of date by the next meeting.

What changes after this course

Your team builds each dossier around what the Federal Joint Committee, the Haute Autorité de Santé and other payers will ask, and sets the launch order to protect your price. You hold a certificate per learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

Market access pharma training: what this course gives your people

Your market access team opens the German dossier already knowing which comparator the Federal Joint Committee will accept under the Arzneimittelmarkt-Neuordnungsgesetz. In France they write for the Haute Autorité de Santé with the two ratings in mind, the actual benefit rating and the improvement rating, so the Economic Committee for Health Products finds fewer gaps to push on during price talks.

Finance directors put the United Kingdom voluntary scheme rebate and the statutory scheme into the forecast before the board asks. They know why an Italian regional budget can hold back patients after the national reimbursement decision, and they mark that delay in the revenue line instead of explaining it in the next quarterly review.

Pricing managers set the launch order so a low price from the Interministerial Commission on Drug Prices in Spain does not become the benchmark for every other country. They model what International Reference Pricing does across borders and keep parallel trade from draining the high-price markets.

In the room with a payer, your team has an answer ready when the objection is that the drug costs too much. They bring a managed entry agreement or an outcomes-based proposal, and they know how health technology assessment evidence, including real-world data, backs it up. They adjust the plan when European Union pharmaceutical reform changes the rules.

Who needs market access pharma training

  • Business Development Manager

    Before you recommend an acquisition, you check whether the target's trial data can earn an added benefit rating from the German Federal Joint Committee, and what that means for the price you can expect in Europe.

  • Market Access Specialist

    You write the submission for the technology appraisal committee at the National Institute for Health and Care Excellence and meet its cost-effectiveness questions in the first draft, not in the rejection letter.

  • Pricing Manager

    You go into price talks with the Italian Medicines Agency with a managed entry agreement already drafted, so a discount is agreed without exposing your public list price in the other countries.

  • Finance Director

    You build the annual European forecast with the Spanish price decision and the United Kingdom voluntary scheme rebate already in it, so the board sees fewer revisions.

Roles: Owner, CEO and board, Business development and export sales, Finance, pricing and tenders

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Map the steps and dates of a German early benefit assessment from dossier submission to the negotiated price.
  2. Calculate how a Spanish price decision spreads to other countries through International Reference Pricing.
  3. Draft the clinical value argument that the Haute Autorité de Santé rates with its actual benefit and improvement ratings.
  4. Answer the cost-effectiveness objections of a United Kingdom technology appraisal committee, with your model assumptions ready to defend.
  5. Design a launch sequence that limits International Reference Pricing and parallel trade risk.
  6. Propose a managed entry agreement to the Italian Medicines Agency during price negotiations.
  7. Compare a rebate under the United Kingdom voluntary scheme with the statutory scheme for the same product.

What the company gets

  • Your market access dossiers answer the payer's likely objection before the first negotiation meeting starts.
  • Avoidable rejections at the Federal Joint Committee or a technology appraisal committee stop eating into the months you have on patent.
  • One low national price no longer travels unchecked through International Reference Pricing to the rest of your European portfolio.
  • Your launch order is written down, so parallel trade from low-price markets has less room to drain profit in high-price ones.
  • Each learner holds a certificate, and the training record gives you a file to show a manager or an auditor.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 10 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 40 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard4 h 10 min25 min a module, for regulatory, quality and business-development staff
Expanded8 h 20 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing1 h 40 min
Business development and export salesBriefing1 h 40 min
Finance, pricing and tendersBriefing1 h 40 min

Market access pharma course outline: 10 modules

10 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Compare how Europe's big markets set and reimburse the price of a pill

    • How to read a pricing system fast: who decides, on what evidence, and who pays.
    • Why the same dossier wins in one country and stalls in another, and how to spot it before filing.
    • What value-based pricing means for your launch timeline in each of the big markets.
  2. 2Pass the German early benefit assessment at the Federal Joint Committee

    • How to choose the comparator the Federal Joint Committee will accept before you write the dossier.
    • Why a missing patient subgroup can cost you the added benefit rating, and how to prevent it.
    • What to expect when you negotiate with the National Association of Statutory Health Insurance Funds.
  3. 3Secure your French price after the Haute Autorité de Santé review

    • Why the actual benefit rating decides if you are reimbursed and the improvement rating decides your price.
    • How to answer the Transparency Committee's draft opinion before it becomes final.
    • What the Economic Committee for Health Products asks for before it agrees a price.
  4. 4Meet the evidence a United Kingdom technology appraisal demands

    • How to show a cost per quality-adjusted life year that the appraisal committee cannot pick apart.
    • Why the voluntary scheme rebate on branded medicine sales belongs in your forecast from day one.
    • When the statutory scheme applies instead of the voluntary scheme, and what that changes.
  5. 5Clear the Italian Medicines Agency's Scientific Economic Committee

    • How to frame cost-effectiveness data for the Italian Medicines Agency's Scientific Economic Committee.
    • Why Italian regional budgets can hold back access after national reimbursement, and how to plan for it.
    • What to do when Italian price talks stall on a cost-effectiveness question.
  6. 6Overcome Spanish price and regional formulary hurdles in hospitals

    • How to prepare for the Interministerial Commission on Drug Prices before it caps your first Spanish price.
    • What each regional health authority wants to see before your drug reaches a hospital formulary.
    • Why Spanish reference price clusters can cut your price once generics enter, and how to plan for the drop.
  7. 7Sequence launches so International Reference Pricing cannot sink your price

    • How to order your launches so a low price in one country does not become everyone's benchmark.
    • The launch order that keeps parallel trade from draining your high-price markets.
    • What the European Union Health Technology Assessment Regulation changes for your next filing.
  8. 8Structure clinical evidence that European health technology assessors accept

    • Which clinical endpoints European assessors accept, and which come back with questions.
    • How to build a cost-effectiveness model that holds when the payer changes your assumptions.
    • When real-world evidence rescues a thin dossier and when it only invites more questions.
  9. 9Counter payer objections in national price negotiations with a ready answer

    • When a confidential discount protects your list price and when it only invites the next demand.
    • The managed entry agreement that turns a hesitant payer into a signatory.
    • What to say when a payer tells you the drug costs too much.
  10. 10Adapt your pricing strategy to new European pharmaceutical policies

    • How an outcomes-based agreement moves financial risk away from the payer and earns a yes.
    • The parts of the European Union pharmaceutical reform that reach your margins, and when.
    • How to price a one-time gene therapy in payment systems built for monthly pills.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about market access pharma training

What is the EU HTA Regulation and when does it apply?

Regulation (EU) 2021/2282 on health technology assessment has applied since 12 January 2025. It introduces joint clinical assessments carried out at EU level, starting with new cancer medicines and advanced therapy medicinal products, then extending to orphan medicines and later to more products. Pricing and reimbursement decisions stay national, but each country must take the joint report into account in its own assessment.

How does international reference pricing affect a European launch?

Many European countries set or cap their prices by looking at the prices of the same medicine in a basket of other countries. A low price agreed in one market can therefore pull prices down elsewhere. Companies plan the order of launches with this in mind, often starting in countries with higher prices or freer pricing. This course shows how to sequence entry and defend the price.

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

10 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 40 min in the briefing length and 8 h 20 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for BD, finance, management. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 90 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team